TARO PHARMACEUTICAL INDUSTRIES LTD. Taro Pharmaceutical Industries Ltd. Share Price Börse Stuttgart
Equities
TAL
IL0010827181
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.8 EUR | -0.51% |
|
+0.52% | +4.84% |
| 05-23 | Taro Pharmaceutical's Shareholders Approve Merger With Sun Pharmaceutical | MT |
| 05-22 | Transcript : Taro Pharmaceutical Industries Ltd. - Shareholder/Analyst Call |
| Sales 2024 | 629M 581M 49.43B | Sales 2025 * | - | Capitalization | 1.61B 1.48B 126B |
|---|---|---|---|---|---|
| Net income 2024 | 53M 48.93M 4.16B | Net income 2025 * | - | EV / Sales 2024 | 2.53 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 |
29.6
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 17.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on Taro Pharmaceutical Industries Ltd.
More recommendations
More press releases
| 1 week | -0.51% | ||
| Current month | -1.52% | ||
| 1 month | -1.52% | ||
| 3 months | +1.57% | ||
| 6 months | +19.02% | ||
| Current year | +4.30% |
1 week
38.60
39.00
1 month
38.2039.20
3 years
20.6062.00
5 years
20.6087.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 30/11/16 | |
William Coote
DFI | Director of Finance/CFO | 69 | 31/12/07 |
Richard Glaze
CTO | Chief Tech/Sci/R&D Officer | 58 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Stein
BRD | Director/Board Member | 73 | 31/01/20 |
| Chairman | 68 | 21/09/10 | |
| Director/Board Member | 67 | 31/08/10 |
| Date | Price | Change |
|---|---|---|
| 30/05/24 | 38.8 | -0.51% |
| 29/05/24 | 39 | +0.52% |
| 28/05/24 | 38.8 | 0.00% |
| 27/05/24 | 38.8 | 0.00% |
| 24/05/24 | 38.8 | -0.51% |
Delayed Quote Börse Stuttgart, May 30, 2024 at 06:03 pm
More quotes
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
Sector
Pharmaceuticals
Calendar
23/07/2024
- Q1 2025 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
42.44
USD
Average target price
43
USD
Spread / Average Target
+1.32%
| 1st Jan change | Capi. | |
|---|---|---|
| +39.82% | 731B | |
| +31.34% | 586B | |
| -7.31% | 348B | |
| +14.23% | 319B | |
| +0.86% | 273B | |
| +13.47% | 235B | |
| -6.63% | 203B | |
| +7.49% | 202B | |
| +4.51% | 159B |
- Stock Market
- Equities
- TARO Stock
- TAL Stock
